检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:田嘉禾[1,2,3,4] 张锦明[1,2,3,4] 侯庆田 欧阳巧洪[1,2,3,4] 川玲 何义杰[1,2,3,4]
机构地区:[1]中国人民解放军总医院核医学科 [2]邯郸钢铁公司职工总医院 [3]中国人民解放军304医院 [4]北京海军总医院
出 处:《同位素》1998年第2期100-105,共6页Journal of Isotopes
基 金:国际原子能机构区域合作计划(CRP)资助课题
摘 要:通过国际原子能机构支持的多中心协作,80例癌性骨痛患者接受单次153Sm-EDTMP注射,观察单次注射两种不同剂量37GBq/g或18.5GBq/g对癌性骨痛治疗的效果及副作用。以止痛剂用量变化、主观止痛感觉、局部功能改进、化验等临床指标,连续观察16周。除7例病人在观察期间死亡外,73例存活者中,止痛有效率86.3%;两种剂量的止痛效果、止痛时间、副作用类型及程度等指标一致;用药后疗效持续时间(8.2±4.5)周;50%病例有血相改变,10例有肝功改变;副作用均在4-6周内恢复;10例止痛无效,其中9例为男性,6例肺癌。结果证实单次153Sm-EDTMP注射是有效的骨痛姑息治疗技术;但对终晚期或伴其他组织转移病例,没有根本性改善作用;止痛疗效与副作用均与剂量无关;男性、肺癌病例治疗无效可能性大。用153Sm-EDTMP治疗癌性骨痛,确实需要进一步客观、科学评价。ifferent dosages of 153SmEDTMP are injected intravenously into 80 patients of bone pain caused by metastases. The patients are selected according to IAEA creteria and received 153SmEDTMP in dosage of 37 GBq/g or 18.5 GBq/g. The efficacy and the sideeffects are evaluated in the following 16 weeks. Improvement of symptom, general condition and change of analgestic concumption are carefully recorded, so are the Lab findings. Seven patients died before the end of the study. In the rest 73 cases, 63 cases show the evidence of palliation, the total response rate after single dose of 153SmEDTMP is 86.3%. The effect persisted for 8.2±4.5 weeks. Nearly 50% of the cases have blood count drops, 10 cases have the evidence of liver damage. All sideeffects disappeared after 6-8 weeks. 9 of 10 nonresponding cases are male, 6 of them suffer from lung cancer. In conclusion, single injection of 153SmEDTMP is effective in treating painful bone metastases, the efficacy and sideeffects are both dosageindependents; male or lung cancer might bear higher risk of being not responding to the therapy. A deeply insighted study is justified for further verification of 153SmEDTMP palliative therapy.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.229